News
-
-
-
-
-
-
-
-
-
-
PRESS RELEASE
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
NewAmsterdam Pharma and Menarini Group receive positive CHMP opinion recommending marketing authorization for Ubeslo and Evlarco in Europe. Milestone for cardiovascular disease treatment